Abstract
Muscimol, thought to be a agonist of gamma-aminobutyric acid (GABA), was administered to eight neuroleptic-free subjects with tardive dyskinesia. At oral dose levels from 5 to 9 mg, involuntary movements were consistently attenuated, usually in the absence of sedation. These results support the view that pharmacologic attempts to stimulate GABA-mediated synaptic transmission may afford symptomatic relief to patients with tardive dyskinesia.
MeSH terms
-
Adult
-
Aged
-
Antipsychotic Agents / adverse effects
-
Dopamine / physiology
-
Drug Evaluation
-
Dyskinesia, Drug-Induced / drug therapy*
-
Dyskinesia, Drug-Induced / etiology
-
Dyskinesia, Drug-Induced / physiopathology
-
Extrapyramidal Tracts / drug effects
-
Female
-
Humans
-
Male
-
Middle Aged
-
Muscimol / pharmacology
-
Muscimol / therapeutic use*
-
Oxazoles / therapeutic use*
-
Receptors, Dopamine / drug effects
-
Receptors, Dopamine / physiology
-
Schizophrenia / drug therapy
-
Stimulation, Chemical
-
Synaptic Transmission / drug effects
-
gamma-Aminobutyric Acid / pharmacology
-
gamma-Aminobutyric Acid / physiology
Substances
-
Antipsychotic Agents
-
Oxazoles
-
Receptors, Dopamine
-
Muscimol
-
gamma-Aminobutyric Acid
-
Dopamine